Cannara Biotech (LOVE) investor relations material

Financial performance and market position

• 21 consecutive quarters of positive adjusted EBITDA; latest net revenue nearly CAD32m and adjusted EBITDA over CAD8.5m, a 27% margin.

• Three brands generated over CAD130m in revenue since launch in 2021; over 50% of revenue came from outside Québec, and estimated retail sales ranking reached #6 as of August.

• Management and board ownership exceeds 50%; domestic market share cited at 4.5%.

Capacity and investment plans

• Valleyfield has 24 grow rooms, with 15 active; the plan targets 18 open by the end of 2027.

• FY2027 investment of CAD30m targets processing first, followed by cultivation; funding includes a syndicated credit facility from BMO and TD.

• EU GMP processing-center construction is scheduled to finish in January 2027; inspections are expected during 2027, with certification hoped for by January 2028.

• Remaining rooms and rooftop greenhouse capacity will be developed in line with visible demand and attractive domestic or international economics.

Curaleaf and international growth

• Curaleaf supply agreement increased from CAD21m over two years in July 2026 to CAD34m in October 2026.

• Curaleaf sponsors the EU GMP application; certification could enable in-house processing and broaden international opportunities, subject to economics.

• Growth plans prioritize domestic market share while assessing incremental international sales against visible demand and risk-adjusted returns.